| Arthritis, Psoriatic
Rinvoq vs Enbrel
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Rinvoq vs Enbrel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEnbrel has a higher rate of injection site reactions vs Rinvoq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Enbrel but not Rinvoq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rinvoq
Enbrel
At A Glance
Oral
Once daily or twice daily (pediatric oral solution)
JAK inhibitor
SC injection
Once weekly
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Dermatitis, Atopic
- Ulcerative Colitis
- Crohn Disease
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Juvenile polyarthritis
- Giant Cell Arteritis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Psoriasis vulgaris
- Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Negative
- Juvenile psoriatic arthritis
Dosing
Rheumatoid Arthritis 15 mg orally once daily
Arthritis, Psoriatic - Adults 15 mg orally once daily
Arthritis, Psoriatic - Pediatric 2 to <18 years Dosing based on weight: 10-<20 kg: 3 mg oral solution twice daily; 20-<30 kg: 4 mg oral solution twice daily; >=30 kg: 6 mg oral solution twice daily or 15 mg tablet once daily
Dermatitis, Atopic - Adults <65 years 15 mg orally once daily; may increase to 30 mg once daily if inadequate response
Dermatitis, Atopic - Adults >=65 years 15 mg orally once daily
Ulcerative Colitis - Induction 45 mg orally once daily for 8 weeks
Ulcerative Colitis - Maintenance 15 mg orally once daily; may use 30 mg once daily for refractory, severe, or extensive disease
Crohn Disease - Induction 45 mg orally once daily for 12 weeks
Crohn Disease - Maintenance 15 mg orally once daily; may use 30 mg once daily for refractory, severe, or extensive disease
Ankylosing spondylitis 15 mg orally once daily
Non-Radiographic Axial Spondyloarthritis 15 mg orally once daily
Juvenile polyarthritis Dosing based on weight: 10-<20 kg: 3 mg oral solution twice daily; 20-<30 kg: 4 mg oral solution twice daily; >=30 kg: 6 mg oral solution twice daily or 15 mg tablet once daily
Giant Cell Arteritis 15 mg orally once daily in combination with tapering corticosteroids; may continue as monotherapy after corticosteroid discontinuation
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once weekly, with or without MTX
Psoriasis vulgaris 50 mg SC twice weekly for 3 months (loading), then 50 mg SC once weekly (maintenance)
Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Negative, Juvenile psoriatic arthritis 0.8 mg/kg SC once weekly, maximum 50 mg per week
Contraindications
- Known hypersensitivity to upadacitinib or any excipients
- Sepsis
Adverse Reactions
Most common (>=3%) - Rheumatoid Arthritis Upper respiratory tract infection, nausea, cough, pyrexia
Most common (>=3%) - Atopic Dermatitis Upper respiratory tract infection, acne, herpes simplex, headache, increased blood creatine phosphokinase, cough, hypersensitivity, folliculitis, nausea, abdominal pain
Most common (>=3%) - Ulcerative Colitis Induction Upper respiratory tract infection, acne, increased blood creatine phosphokinase, neutropenia, rash, elevated liver enzymes, lymphopenia
Most common (>=3%) - Ulcerative Colitis Maintenance Upper respiratory tract infection, increased blood creatine phosphokinase, pyrexia, neutropenia, elevated liver enzymes, rash, herpes zoster, folliculitis, hypercholesterolemia, influenza, herpes simplex
Most common (>=3%) - Crohn Disease Induction Upper respiratory tract infection, anemia, acne, pyrexia, increased blood creatine phosphokinase, influenza, herpes simplex
Most common (>=3%) - Crohn Disease Maintenance Upper respiratory tract infection, pyrexia, herpes zoster, headache, acne, gastroenteritis, fatigue, increased blood creatine phosphokinase
Most common (>=5%) - Giant Cell Arteritis Upper respiratory tract infection, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, nausea
Serious Serious infections, opportunistic infections, tuberculosis, malignancies, major adverse cardiovascular events, thrombosis, gastrointestinal perforations, hypersensitivity reactions, eczema herpeticum
Most common Infections (upper respiratory tract infection, sinusitis, influenza), injection site reactions (erythema, itching, pain, swelling)
Serious Serious infections (pneumonia, cellulitis, septic arthritis, sepsis), neurologic events, congestive heart failure, hematologic events
Postmarketing Pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, aplastic anemia, congestive heart failure, inflammatory bowel disease, angioedema, autoimmune hepatitis, macrophage activation syndrome, systemic vasculitis, sarcoidosis, lupus-like syndrome, melanoma, non-melanoma skin cancers, Merkel cell carcinoma, convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, uveitis, scleritis, glomerulonephritis, interstitial lung disease, Stevens-Johnson syndrome, toxic epidermal necrolysis, opportunistic infections
Pharmacology
Upadacitinib is a JAK inhibitor that modulates intracellular signaling by preventing JAK-mediated phosphorylation and activation of STATs, thereby influencing immune cell function and hematopoiesis.
Etanercept is a dimeric soluble form of the human p75 TNF receptor that inhibits binding of TNF-alpha and TNF-beta (lymphotoxin alpha) to cell surface TNF receptors, rendering TNF biologically inactive and modulating downstream inflammatory responses including adhesion molecule expression, cytokine levels, and matrix metalloproteinase levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rinvoq
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Enbrel
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Rinvoq
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Enbrel
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Rinvoq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Enbrel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCo-Pay Relief Rheumatoid Arthritis Fund
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Enbrel.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RinvoqView full Rinvoq profile
EnbrelView full Enbrel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.